Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Atlanta
        • Atlanta Leadership
        • Atlanta Contacts
      • Caribbean
        • Caribbean Leadership
        • Caribbean Contacts
      • Chicago
        • Chicago Leadership
        • Chicago Contacts
      • Dallas
        • Dallas Leadership
        • Dallas Contacts
      • Detroit
        • Detroit Leadership
        • Detroit Contacts
      • El Paso
        • El Paso Leadership
        • El Paso Contacts
      • Headquarters
      • Houston
        • Houston Leadership
        • Houston Contacts
      • Los Angeles
        • Los Angeles Leadership
        • Los Angeles Contacts
      • Louisville
        • Louisville Leadership
        • Louisville Contacts
      • Miami
        • Miami Leadership
        • Miami Contacts
      • New England
        • New England Leadership
        • New England Contacts
      • New Jersey
        • New Jersey Contacts
      • New Orleans
        • New Orleans Leadership
        • New Orleans Contacts
      • New York
        • New York Leadership
        • New York Contacts
      • Omaha
        • Omaha Leadership
        • Omaha Contacts
      • Philadelphia
        • Philadelphia Leadership
        • Philadelphia Contacts
      • Phoenix
        • Phoenix Leadership
        • Phoenix Contacts
      • Rocky Mountain
        • Rocky Mountain Contacts
      • San Diego
        • San Diego Leadership
        • San Diego Contacts
      • San Francisco
        • San Francisco Contacts
      • Seattle
        • Seattle Contacts
      • St. Louis
        • St. Louis Leadership
        • St. Louis Contacts
      • Washington, DC
        • Washington Leadership
        • Washington Contacts
    • DEA Museum
    • Foreign Offices
      • Africa
      • Andean
      • Caribbean
      • Europe
      • Far East
      • Middle East
      • North and Central America
      • Southern Cone
    • Operational Divisions
      • Aviation Division
      • Diversion Control Division
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
        • Leadership
        • Mission
        • Services
        • Contacts
      • Forensic Sciences
        • Computer Forensics Program
        • Environmental Management
        • Laboratories
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
        • State and Local Task Forces
    • Education and Prevention
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Red Ribbon
        • Kiki and the History of Red Ribbon Week
        • Red Ribbon Toolkit - Resources For Your Community
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
      • Special Agent Job Announcements
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • How to Apply
      • Employment Requirements
      • Equal Opportunity Employer
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
  • Resources
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Search
  • Full Menu

Main Menu

  • Who We Are
  • What We Do
  • Careers
  • Resources
  • Submit A Tip
  • Get Updates
  • Scam Alert
  • English
  • ES

Drug Enforcement Administration

Jarod A. Forget Special Agent in Charge
Washington, DC
@DEAWashingtonDC
May 12, 2022
Contact: Public Information Office
Phone Number: (571) 362-1934
For Immediate Release

Consent Decree Approved Between the United States and Baltimore-Based Pharmacy and Pharmacist Alleged to Have Illegally Dispensed Controlled Substances

United States Alleges that the Pharmacist and Pharmacy Ignored Red Flags Indicating the Prescriptions Were Not Legitimate

Baltimore, Md. - U.S. District Judge Richard D. Bennett approved the United States’ consent decree with Ketan K. Dankhara, a Baltimore-based pharmacist, and Falls RX, LLC d/b/a Ultra Care Pharmacy Baltimore (“Ultra Care”), resolving the United States’ civil allegations that Dankhara and Ultra Care violated the Controlled Substances Act (“CSA”) in illegally dispensing controlled substances.

The consent decree was announced by Jarod Forget, Special Agent in Charge of the DEA Washington Division, and United States Attorney for the District of Maryland Erek L. Barron.

“Our pharmacists play a key role in the proper dispensing of controlled substances, helping patients, and protecting us all against the dangers of drug diversion,” stated Jarod A. Forget, Special Agent in Charge of the Washington Division.  “When pharmacists ignore ‘red flags,’ their dispensing contributes to the opioid epidemic.  We at the DEA are working hard, every day, to investigate such behavior, and keep our communities safe.”

“Under the Controlled Substances Act, pharmacists and pharmacies assume a critical gatekeeping function to prevent the diversion of controlled substances,” said U.S. Attorney Erek L. Barron.  “Just as prescribers cannot use their prescription pad as a blank checkbook to write prescriptions for controlled substances, the CSA and its regulations make clear that pharmacists have a corresponding responsibility to ensure the legitimacy of the prescriptions they fill.  We will hold responsible those in the supply chain—manufacturers, distributors, prescribers, and retail pharmacies—who violate the CSA and illegally distribute controlled substances, fueling Maryland’s drug addiction epidemic.”

The Government alleges that shortly after Ultra Care opened for business, Dankhara knowingly filled fraudulent prescriptions for controlled substances, ignoring red flags that should have acted as warning signs that the prescriptions were not legitimate.  More specifically, on several occasions between at least May and September 2020, an individual came to Ultra Care and attempted to fill controlled substance prescriptions for a number of people at the same time, many of whom had never previously been to the pharmacy.  At least several dozen of these prescriptions were fraudulent.  Some of the fraudulent prescriptions were for the same drug, strength, and quantity, and were from the same prescriber and some were prescribed by an OB/GYN to individuals who were biologically male.  Notwithstanding these red flags, Dankhara made no attempt to determine whether the prescriptions were legitimate, nor did he otherwise resolve the red flags.  Further, on at least one occasion, Dankhara indicated on a fraudulent prescription that he spoke with the prescriber when, in fact, Dankhara later admitted that he had no such conversation.  The Government alleges that Ultra Care is liable for these deficiencies. 

Under the consent decree, in addition to paying a $15,000 civil monetary penalty, Dankhara and Ultra Care are required to identify certain red flags—including when a patient presents prescriptions written in the names of other people without a valid justification, and when the patient is biologically male and presents prescriptions from an obstetrician or gynecologist.  Before filling prescriptions bearing those red flags, the consent decree requires Dankhara and Ultra Care to document in detail any indications of abuse or diversion and the steps they took to ensure that the prescription was valid and was issued for a legitimate medical purpose, and that the prescription would not be abused or diverted for illegitimate purposes.  Under the consent decree, if the DEA determines that Dankhara or Ultra Care has violated any provision of the consent decree and/or if Dankhara or the Pharmacy does not implement the corrective action the DEA orders, the DEA can order Dankhara and Ultra Care to cease ordering, distributing, or dispensing controlled substances immediately.

The consent decree is not an admission of liability by Ketan Dankhara or Ultra Care, nor a concession by the United States that its claims are not well-founded.   

The Court’s approval of this consent decree should remind pharmacists and pharmacies that the Department of Justice intends to use all tools at its disposal—both criminal and civil—to combat the controlled substances epidemic which continues to plague the United States, including here in Maryland. 

##

Opioids
  • Facebook
  • Twitter
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Drug Prevention
    • Law Enforcement
    • Diversion Control Division
    • News
  • Careers
    • Overview
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
  • Resources
    • Drug Information
    • Employee Assistance Program
    • Equal Opportunity Employer
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
  • Policies
    • Accessibility, Plug-ins & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
Home

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster